Evidence map›Paper›PMID 37310405›Full record

ArticleAging2023

Network medicine framework identified drug-repurposing opportunities of pharmaco-active compounds of Angelica acutiloba (Siebold & Zucc.) Kitag. for skin aging.

Jiaxin Mo, Zunjiang Li, Hankun Chen, Zhongyu Lu, Banghan Ding, Xiaohong Yuan, Yuan Liu, Wei Zhu

Abstract read
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaxin MoThe Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou Province 510006, China.
Zunjiang LiThe Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou Province 510006, China.
Hankun ChenGuangzhou Qinglan Biotechnology Co. Ltd., Guangzhou Province 515000, China.
Zhongyu LuThe Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou Province 510006, China.
Banghan DingThe Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou Province 510006, China.
Xiaohong YuanGuangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou Province 510120, China.
Yuan LiuGuangzhou Huamiao Biotechnology Research Institute Co. Ltd., Guangzhou Province 510000, China.
Wei ZhuGuangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou Province 510120, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing incidence of skin aging has highlighted the importance of identifying effective drugs with repurposed opportunities for skin aging. We aimed to identify pharmaco-active compounds with drug-repurposing opportunities for skin aging from Angelica acutiloba (Siebold & Zucc.) Kitag. (AAK). The proximity of network medicine framework (NMF) firstly identified 8 key AAK compounds with repurposed opportunities for skin aging, which may exert by regulating 29 differentially expressed genes (DGEs) of skin aging, including 13 up-regulated targets and 16 down-regulated targets. Connectivity MAP (cMAP) analysis revealed 8 key compounds were involved in regulating the process of cell proliferation and apoptosis, mitochondrial energy metabolism and oxidative stress of skin aging. Molecular docking analysis showed that 8 key compounds had a high docked ability with AR, BCHE, HPGD and PI3, which were identified as specific biomarker for the diagnosis of skin aging. Finally, the mechanisms of these key compounds were predicted to be involved in inhibiting autophagy pathway and activating Phospholipase D signaling pathway. In conclusion, this study firstly elucidated the drug-repurposing opportunities of AAK compounds for skin aging, providing a theoretical reference for identifying repurposing drugs from Chinese medicine and new insights for our future research.

Indexed as

AngelicaSkin AgingDrug RepositioningMolecular Docking SimulationSignal TransductionAngelica acutiloba (Siebold & Zucc.) Kitag.drug-repurposing opportunitiesnetwork medicine frameworkpharmaco-active compoundsskin aging

Identifiers

PMID37310405
PMCPMC10292898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.